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Recent WHO guidelines recommend immediate initiation of lifelong antiretroviral therapy (ART) in all
children below 5 years, irrespective of immune/clinical status, to improve access to paediatric ART. Interim
trial results provide strong evidence for immediate ART during infancy because of high short-term risk of
mortality and disease progression, but there is wider debate regarding the potential risks and benefits of
immediate ART in asymptomatic children aged above 1 year. Concerns include long-term toxicities and
treatment failure, particularly in resource-constrained settings with limited paediatric treatment options.
Recent findings
Benefits of immediate ART among infants appear to be maintained in the mid-term to long-term, with low
risk of treatment failure, and better neurodevelopmental outcomes. In contrast, a trial reported no benefits
of immediate versus deferred ART in asymptomatic children aged above 1 year. However, observational
studies suggest that ART initiation at older ages and lower CD4 reduces the probability of immune
reconstitution, with unclear implications on risk of clinical events or treatment change. A recent trial on
treatment interruption following early intensive ART suggest that this may be a safe alternative approach.
Summary
Although there are clear benefits of immediate ART among infants, there remains conflicting evidence on
the benefits for older children.
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In 2011, an estimated 3.3 million children aged
below 15 years were living with HIV, of whommore
than 90% lived in sub-Saharan Africa, and the vast
majority were infected through mother-to-child
transmission [1]. Despite the rapid scale up of inter-
ventions for prevention of mother-to-child trans-
mission of HIV, coverage in the top 21 Global Plan
priority countries remains highly variable, ranging
from 9% tomore than 95% [2].Within these priority
countries, there were an estimated 210000 children
newly infected in 2012 alone [3]. Without antire-
troviral therapy (ART), up to 50% of childrenwill die
by 2 years of age in resource-limited settings [4,5
&
].
Yet, the global coverage of ART among children
continues to lag behind at 28% of those in need
of treatment, as compared to 58% in adults [6].
The WHO recommendations on when to start
ART in childrenhave been revised four times over the
past decade, each time relaxing the eligibility criteria
to higher CD4 levels, and more recently increasing
the age for immediate ART from all those belowilliams & Wilkins. Unau
Health | Lippincott Williams & Wilki2 years to all below 5 years, irrespective of clinical
or immune status [7] (Table 1) [7–11]. Older children
are recommended to start ARTwhenCD4 is less than
500 cells (an increase from<350 cells), in alignment
with adult guidelines, and following studies which
showed similar risk of disease progression in children
aged above 5 years as young adults [12].
In contrast, the United States and European
Paediatric European Network for Treatment of AIDS
(PENTA) paediatric guidelines only recommend
immediate ART for all infants below 12 months,thorized reproduction of this article is prohibited.
ns www.co-hivandaids.com
CKEY POINTS
 Strong evidence of benefits of immediate lifelong ART
in infants in mid-term to long-term AIDS-free survival,
with good response to therapy, and benefits in some
neurodevelopmental outcomes.
 Conflicting evidence of benefit of immediate ART in
children aged above 1 year: a clinical trial reported no
benefit while observational data suggest benefit for
long-term immune reconstitution.
 Treatment-sparing strategies including early intensive
ART in infancy followed by treatment interruption, to
minimize long-term toxicity and risk of drug resistance,
appears to be safe in children but requires
close monitoring.
Does antiretroviral treatment at high CD4 counts reduce disease risk for HIV-positive patients?whereas older children are recommended to initiate
ART based on clinical and immune status [13,14].
However, theWHO recommendations are based
on a public health approach, taking into account
programmatic issues in resource-limited settings,
such as difficulties in provision of CD4 testing
and high rates of loss-to-follow-up among children
not eligible for treatment [15,16,17
&
]. Furthermore,
recent data suggest that a large number of children
still present late for treatment, when severely immu-
nocompromised and at advanced disease stage [18],
with high risk of mortality during screening and in
the first year of ART [15], especially in those aged
below 2 years [19,20].
With the aim to minimize the risk of disease
progression and mortality, under the consolidated
WHO guidelines HIV-infected children would
initiate lifelong ART from infancy. In this review,
we focus on the most recent evidence on the risks
and benefits of earlier initiation of ART in threeopyright © Lippincott Williams & Wilkins. Unautho
Table 1. Changes in World Health Organization recommendatio
therapy by age from 2003 to 2013
Age <12 months 12–23 mont
WHO guidelines
2003 [8] CD4% <20% <15%
Absolute CD4 NA NA
2006 [9] CD4% <25% <20%
Absolute CD4 <1500cells/mm3 <750cells/m
2008 [10] CD4% All <20%
Absolute CD4 All <750cells/m
2010 [11] CD4% All All
Absolute CD4 All All
2013 [7] CD4% All All
Absolute CD4 All All
88 www.co-hivandaids.commain areas: survival and AIDS-free survival; immune
restoration, as this is closely associated with risk
of disease progression; and neurodevelopmental
outcomes, because of their important implications
on quality of life. Lastly, we briefly review the
latest evidence on treatment-sparing strategies.
This is critical to minimize long-term toxicities
and to preserve future treatment options, particu-
larly in resource-limited settings wherein often only
first and second-line regimens are available [21].WHEN TO START ANTIRETROVIRAL
THERAPY: SURVIVAL AND AIDS-FREE
SURVIVAL
Up until 2008, the WHO recommendations on
when to initiate ART in children were largely based
on observational data which demonstrated younger
age and poorer immune status as the main predic-
tors of risk of disease progression and death, as well
as higher risk in untreated children in sub-Saharan
Africa compared with Europe and the USA [22,23].
To date, there have only been two clinical trials
assessing when to start ART in children, both con-
ducted in low or middle-income countries.
The Children with HIV early antiretroviral
therapy (CHER) trial in South Africa randomized
377 asymptomatic HIV-infected infants (CD4>
25% at median 7 weeks of age) to immediate
initiation of ART before 12 weeks of age or deferred
ART based on WHO 2006 clinical or CD4 criteria.
After a median of only 40 weeks, there was a 76%
[95% confidence interval (CI), 49–89%, P<0.001]
reduction inmortality and 75% reduction in disease
progression (95%CI, 59–85%, P<0.001) in the early
treatment arm [24], and these results were con-
firmed in the final analysis at 4 years of follow-up
[25
&&
] (Table 2) [25
&&
,26,27
&
,28
&&
,29
&
].rized reproduction of this article is prohibited.
ns on immunological threshold of when to start antiretroviral
hs 24–35 months 36–59 months 60 months
<15% <15%
m3 <350cells/mm3 <200cells/mm3
<20% <15%
m3 <350cells/mm3 <200cells/mm3
25% NA
<750cells/mm3 350cells/mm3
All All NA
All All 500cells/mm3
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the deferred treatment arm was among untreated
children who died before meeting the clinical/
immune criteria for ART. Following the interim
result of this trial, the WHO, United States and
PENTA guidelines were all revised in 2008 to recom-
mend immediate ART in all HIV-infected infants
under 12months, irrespective of clinical or immune
status [10]. In the WHO 2010 guidelines, this was
extended to all children under 24 months [11], for
programmatic reasons and also in recognizing
that observational data indicate the higher risk of
AIDS and death extend to young children below
2 years [22,23]. Importantly, final results of the
CHER trial showed that very few children in the
early ART arms switched to second line (4 of 252),
although this may have been partly because of the
treatment-sparing strategy in which infants on early
ART were randomized to treatment interruption
after 40 or 96 weeks of ART (see later section) [25
&&
].
The Paediatric Randomized Early vs. Deferred
Initiation in Cambodia and Thailand (PREDICT)
study, randomized 284 children, aged 1–12 years
with CD4 of 15–24% and no AIDS-defining illness
to immediate ART or deferred treatment until CD4
less than 15% or Centres for Disease Control and
Prevention (CDC) stage C. At 3 years of follow-up,
there was no difference in the AIDS-free survival:
97.9% (95% CI, 93.7–99.3) and 98.7% (95%CI,
94.7–99.7, P¼0.6) in the early and deferred arms,
respectively [28
&&
]. The rate of events was very low
(one death and five CDC C events), and the authors
concluded that the study was underpowered to
detect a difference between the two strategies.
However, there were also no differences between
the two arms in any secondary outcomes: rate of
hospitalization, CDC stage B or C events, virological
suppression, immunological response or neuro-
developmental outcomes, suggesting no significant
benefit of earlier treatment in asymptomatic chil-
dren above 1 year. However, it is important to note
that children in the deferred treatment arm received
CD4 assessments every 3 months and prompt ART
initiation at higher median CD4% as compared to
other studies in comparable routine care settings
[30,31]. Furthermore, this trial included mainly
older surviving children, with a median age of
6.4 years at randomization (only 26% were aged
<3 years and 6% aged 1–2 years); therefore, the
findings may not be generalizable to all children
below 5 years.
In the absence of clinical trial data, the
South Africa International Epidemiologic Database
to Evaluate AIDS collaboration conducted a causal
modelling analysis, using data from the their large
cohort of approximately 3000 children aged 2 torized reproduction of this article is prohibited.
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&
]. The model
estimated mortality over 3 years if the 2013 guide-
lines for immediate ART was implemented as
compared to starting ART when CD4 declined to
less than 25% or less than 750 cell counts as per
routine practice within the cohort. The model
showed no significant benefit in mortality from
the immediate treatment strategy, most likely
because of the relatively low risk of mortality in
children aged 2–5 years with CD4 more than 25%.
In summary, there is limited evidence to support
immediate ART in children aged 2–5 years in
terms of survival or AIDS-free survival. This is partly
reflected in the WHO recommendations, which
state that priority for immediate ART should be
given to children aged less than 2 years or those
aged 2–5 years with advanced disease stage [7].IMMUNOLOGICAL RECONSTITUTION
As most children on ART are now surviving into
adolescence and young adulthood, there is a need to
study the impact of earlier treatment initiation
on long-term response and morbidity. Numerous
studies have shown that children who initiate
ART at low CD4 or older age are less likely to achieve
immune reconstitution to near normal levels, often
defined as CD4 at least 25% [33–35] or at least 30%
[36], which represents the upper threshold for start
of treatment in children above 2 years. Children
who fail to reach this threshold may be vulnerable
to disease progression. However, most studies
have been limited to follow-up of 2–5 years on
ART, and the long-term trajectory of immune
response is unclear.
To address that, one novel study by Lewis et al.
[37
&&
] used data from the PENTA-5 clinical trial,
of 127European/South American children in an
immunological sub-study, to model the CD4
trajectories of children on ART into adulthood.
As expected, the long-term CD4 z-scores were
significantly lower for children starting ART at older
ages and those with lower pre-ART CD4. However,
children starting with lower CD4 cell count at
younger ages had greater capacity for immune
reconstitution as compared to older children,
possibly due to increased thymic activity and a
shorter duration of infection [37
&&
]. The samemodel
was also applied to data from the Antiretroviral
research forWatoto (ARROW) trial, of 1206 children
randomized to clinical-based or clinical and labora-
tory-based monitoring in Uganda and Zimbabwe,
with 4 years of follow-up on ART [38
&
]. Similar
results were observed, whereby higher long-term
CD4 cell counts were predicted for children starting
ART at younger ages and with higher CD4 cellCopyright © Lippincott Williams & Wilkins. Unau
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ART aged above 10 years were unlikely to ever
normalize CD4 cell counts, irrespective of their
CD4 at start of therapy.
These findings are consistent with recent results
from an observational study in Thailand. Among
507 children followed up for a median of 7 years,
22% failed to achieve immune reconstitution
defined as confirmed CD4 of at least 25%, of whom
over half had sustained viral suppression less than
400 copies throughout their follow-up time [39].
Age above 7 years and very low CD4 less than 5%
at start of ART were associated with poor immune
reconstitution, although the impact on clinical
events was not assessed. In contrast, in the PREDICT
trial, composed of similarly older children, there
were no differences in long-term immune response
in the immediate versus deferred ART arms, and
it was unclear if there was an effect of age at start
of therapy [28
&&
].
In summary, observational studies suggest that
delayed initiation of ART until age above 7 years
or when severely immunosuppressed significantly
reduces the probability of immune reconstitution,
although the clinical implications of this remains
unclear. In adult studies, nonimmune response
despite viral suppression has been associated with
increased risk of severe clinical events [40] and death
[41], whereas prolonged periods of immune recon-
stitution (defined as CD4500 cells/mm3) have
been associated with improved life expectancy,
comparable to the general population [42,43].
No equivalent study has yet been conducted in
perinatally infected patients, mainly because of
lack of data on long-term clinical outcomes; this
highlights the need for continued follow-up after
children transfer to adolescent and adult clinics.NEURODEVELOPMENTAL OUTCOMES
There were two recent reviews on neurodevelop-
mental outcomes in perinatally HIV-infected chil-
dren and adolescents [44
&&
,45]. AIDS-defining illness
and low CD4 have been associated with poorer
neurodevelopmental outcomes in resource-rich
and resource-limited settings [46
&
,47
&
]. However,
the debate on whether earlier treatment initiation
improves neurodevelopmental outcomes among
children without advanced disease stage continues.
In the CHER trial’s neurological sub-study, children
in the early ART group had significantly higher
General and Locomotor scores at 11 months
of age as compared to the deferred ART group,
and were comparable to HIV-uninfected controls
[27
&
]. However, differences between the groups were
relatively small, and the mean General andthorized reproduction of this article is prohibited.
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within the normal developmental range.
In the PREDICT trial sub-study, with a median
age 9 years at last examination, there was no
difference in the neurocognitive performance in
the early versus deferred ART groups, despite repeat
measurements throughout the study. Both groups
had poorer outcomes as compared to HIV-exposed
uninfected controls on key measures [29
&
]. How-
ever, it is important to note that these measures
were based on the methods developed in the USA or
Europe and have not been standardized for these
other settings. Also comparisons with HIV-exposed
uninfected controls may be subject to unmeasured
confounders, such as differences in the family set-
tings and access to care, whichmay affect outcomes.
Also the magnitude of differences in outcomes and
their impact on daily function, learning capabilities
and quality of life are unknown.OTHER CONSIDERATIONS: TOXICITIES,
VIROLOGIC FAILURE AND TREATMENT-
SPARING STRATEGIES
As with adults, earlier initiation of lifelong
ART poses potential risks of long-term toxicities,
increased risk of virological failure and limited
treatment options. A fuller discussion of potential
toxicities is beyond the scope of this review. Briefly,
concerns have been raised regarding prolonged
exposure to tenofovir (recommended first line for
children>3 years) and protease inhibitors (lopinavir
is recommended first line for children <3 years)
among children and adolescents because of their
impact on bone mineral density/kidney function
and metabolic disease respectively, during critical
periods of growth and development [48
&
,49,50].
Such concerns are particularly important in
resource-constrained settings wherein there is
limited monitoring of such toxicities.
Recent results from the CHER and PREDICT
trials showvery good long-termvirological suppres-
sion and low rates of switch to second line among
children on immediate ART [25
&&
,26]. However,
data from observational studies in routine care
settings suggest much higher rates of virological
failure in Asia and Africa (range from 19 to 25%
at 3–5 years of ART in settings with routine
virological monitoring) [51,52
&
,53]. Also a recent
meta-analysis reported higher levels of triple-class
virological failure in European adolescents starting
ARTcomparedwith5–9-year olds [54]. In countries,
where only first line and second-line treatment
options are available, this presents a critical
dilemma and has resulted in trials exploring treat-
ment-sparing strategies.opyright © Lippincott Williams & Wilkins. Unautho
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(NEVEREST) trial, wherein children aged below
3 years started ART with lopinavir-based therapy
and continued on this regimen or switched to
nevirapine-based regimen after a prolonged period
of virological suppressionwith the aim of preserving
lopinavir for second line. Results suggested that
those who switched to nevirapine had poorer
virological outcomes but better growth and CD4
responses [55
&&
]. The other strategy was within the
CHER trial, in which children on early ART had a
treatment interruption at 40 or 96 weeks with CD4
and clinical-guided criteria for reinitiation of ART
[25
&&
]. Up to a third of children in the 96 weeks arm
remained off treatment at the end of the study with
good CD4 profiles. The study showed that this
strategy was well tolerated and superior when com-
pared with deferred ART. However, the study was
not powered to detect a difference in outcomes
between the two treatment interruption arms, and
there was no early ART continuous arm to compare
with. These findings suggest that there may be a
future role for early intensive treatment followed by
periods of interruption, but, critically, rely on close
clinical and laboratory monitoring, which is not
available everywhere. Nonetheless, the findings
confirm conclusions from previous studies that,
unlike in adults, treatment interruption in children
appears well tolerated without higher risk of
mortality, serious clinical events [56] or negative
impact on long-term immune/virological response
after reinitiation of ART [57
&
], although further
study is needed.CONCLUSION
With an estimated 300 000 children newly
infected with HIV in 2012 alone, questions
concerning when to start lifelong ART remain
extremely relevant to paediatrics. Although there
is strong evidence of wide ranging benefits
of immediate ART in infants, there remains
conflicting evidence on the benefits of early ART
in asymptomatic children above 1 year. Modelling
studies suggest that delayed ART initiation at
older ages and lower CD4 reduces the probability
of immune reconstitution with unknown implica-
tions for long-term disease progression, highlight-
ing the need for continued follow-up of perinatally
infected patients as they transfer to adolescent
and adult clinics. Lastly, recent trial results
suggest that treatment interruption following
early intensive ART during infancy may be a well
tolerated alternative strategy but requires close
monitoring, which is not available in most of the
affected regions.rized reproduction of this article is prohibited.
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